Noul Co., Ltd.

Noul Co., Ltd. is a South Korean biotechnology company founded in 2015, specializing in AI-powered in vitro diagnostics and remote diagnosis solutions for infectious and non-infectious diseases. The company's flagship miLab™ platform is an advanced digital diagnostic system that automates blood analysis, sample preparation, and AI-driven pathology interpretation. Noul's product portfolio addresses critical global healthcare challenges, focusing on malaria diagnosis, complete blood count (CBC) and cell morphology analysis, and early cervical cancer detection through AI-powered cytology. The company has established international partnerships and distribution agreements, with presence across multiple countries. Noul's technology delivers significant improvements in diagnostic accessibility, speed (>2x reduction in analysis time), and accuracy, with clinical validation demonstrating high sensitivity and specificity. The company is committed to scaling diagnostic innovation globally, with a vision to impact one billion lives by 2030 through timely, accessible diagnostics for resource-limited and developed healthcare settings.